Recently, Signet Therapeutics (Shenzhen) Co., Ltd. has successfully been approved for the 2025 Guangdong-Macau Joint Science and Technology Innovation Funding Project, receivingRMB 1 millionProject funding, used to support “Preclinical Study of Novel FAK Inhibitor SIGX1094R as Monotherapy and in Combination Therapy for Triple-Negative Breast Cancer”。
The Guangdong-Hong Kong-Macao Joint Funding Project for Scientific and Technological Innovation, jointly initiated by the Guangdong Provincial Department of Science and Technology and the Macao Science and Technology Development Fund, focuses on cutting-edge technology fields. It aims to promote collaborative innovation and key technology breakthroughs between Guangdong and Macao. The program has a rigorous evaluation process and offers substantial support (each party provides funding of 1 million RMB or an equivalent amount in Macao pataca).
The Australian partner team for this joint funding is the Sun Heng/Deng Chuxia team from the University of Macau. The Deng Chuxia/Sun Heng team are pioneers in the construction of in vivo and in vitro models of breast cancer and mechanistic research, and have discoveredThe Founding Mechanism of BRCA1 Gene in Breast Cancer, opening a new direction for the treatment of triple-negative breast cancer,His research work has been cited over 90,000 times., is a highly cited scientist representative.
SIGX1094R is the core pipeline independently developed by Signet Therapeutics based on the world's first "Organoid+AI" platform. This drug is the world’s first targeted therapy for diffuse gastric cancer and the first dual-target FAK/SRC inhibitor to enter clinical trials globally. In addition to treating diffuse gastric cancer and advanced ascites, SIGX1094R has also shown potential in treating malignant metastatic cancers such as triple-negative breast cancer, ovarian cancer, and pancreatic cancer. In August 2025, the drug was nominated for the Galien Award (Prix Galien USA), known as the "Nobel Prize of the pharmaceutical industry," making Signet Therapeutics the only Chinese biopharmaceutical company on the list this year.
SIGX1094R has received IND approval from the U.S. FDA and China NMPA, and has successively obtained Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. A Phase I clinical trial was initiated in December 2024 at Peking University Cancer Hospital, where it demonstrated good safety and preliminary anti-tumor activity during the dose-escalation phase of the trial.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI"-powered innovative targeted drug R&D model, and is recognized as a national high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise. The company's founding team consists of top talents from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As first or corresponding authors, they have published over 20 groundbreaking research papers on gastric cancer and esophageal cancer in high-impact journals like Nature, Nature Medicine, and Cancer Cell, with impact factors exceeding 20. SIGNET is a global leader in the field of gastric and esophageal cancer research. Since its establishment in Shenzhen at the end of 2020, the company has raised nearly 220 million yuan in financing and project funding, and holds more than 40 core intellectual properties.
The company currently has four first-in-class drug pipelines and one organoid platform in its portfolio. Its core pipeline, SIGX1094R, is the world's first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China's NMPA, as well as Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. In August 2025, this drug was nominated for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." It is currently undergoing Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world’s first drug to be advanced to the clinical stage through an "organoid + AI" technology platform and is expected to enter Phase II clinical trials by the end of 2025.
Since its establishment at the end of 2020, Signet Therapeutics' forward-looking strategic layout of an "Organoid + AI"-powered technology system for innovative targeted cancer drug development has gained international authoritative recognition. It was featured on the homepage of Fierce Biotech, a globally renowned biotech media outlet, and hailed as the "NEXT Generation" paradigm for cancer drug development. In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal testing with organoid and AI technologies, fully validating the foresight and scientific rigor of the company’s technical layout from four years prior.
1
END
1
